Filtered By:
Education: Study
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 2305 results found since Jan 2013.

Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis
CMAJ Open. 2023 Feb 7;11(1):E118-E130. doi: 10.9778/cmajo.20210119. Print 2023 Jan-Feb.ABSTRACTBACKGROUND: Dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting; however, optimal duration remains uncertain in some situations. We assessed the benefits and harms of extending DAPT beyond 1 year after PCI in clinically important patient subgroups.METHODS: We conducted a systematic review and meta-analysis. We searched electronic databases (Embase, MEDLINE, PubMed, Cochrane Library) and grey literature (from inception to Nov. 5, 2021) and included randomized...
Source: cmaj - February 7, 2023 Category: General Medicine Authors: Jesse Elliott Shannon E Kelly Zemin Bai Becky Skidmore Michel Boucher Derek So George A Wells Source Type: research

Combined assessment of frailty and nutritional status can be a prognostic indicator after percutaneous coronary intervention
In conclusion, patients with both frailty and malnutrition had a higher risk of MACEs after PCI than patients with frailty or malnutrition. Post-PCI patients should be evaluated for combined frailty and malnutrition.
Source: Heart and Vessels - February 6, 2023 Category: Cardiology Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research

Shorter door-to-balloon time, better long-term clinical outcomes in ST-segment elevation myocardial infarction patients: J-MINUET Substudy
CONCLUSION: Shorter DTB time was associated with better long-term clinical outcomes in STEMI patients treated with PPCI in contemporary clinical practice. Further efforts to shorten DTB time are recommended to improve long-term clinical outcomes in STEMI patients.PMID:36736534 | DOI:10.1016/j.jjcc.2023.01.008
Source: Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Ryota Nishio Manabu Ogita Satoru Suwa Koichi Nakao Yukio Ozaki Kazuo Kimura Junya Ako Teruo Noguchi Kazuteru Fujimoto Kazuoki Dai Takashi Morita Wataru Shimizu Yoshihiko Saito Atsushi Hirohata Yasuhiro Morita Teruo Inoue Atsunori Okamura Toshiaki Mano Min Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research

Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta - analysis
CONCLUSION: Shortened DAPT signifcantly reduced the odds of major bleedings in patients undergoing complex PCI, without increasing the ischemic events or mortality. Thus, it could be considered as a safe and feasible option in such patients.PMID:36736730 | DOI:10.1016/j.hjc.2023.01.005
Source: Hellenic Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Anastasios Apostolos Dimitrios Chlorogiannis Georgios Vasilagkos Konstantinos Katsanos Konstantinos Toutouzas Adel Aminian Dimitrios Alexopoulos Periklis Davlouros Grigorios Tsigkas Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research

Shorter door-to-balloon time, better long-term clinical outcomes in ST-segment elevation myocardial infarction patients: J-MINUET Substudy
CONCLUSION: Shorter DTB time was associated with better long-term clinical outcomes in STEMI patients treated with PPCI in contemporary clinical practice. Further efforts to shorten DTB time are recommended to improve long-term clinical outcomes in STEMI patients.PMID:36736534 | DOI:10.1016/j.jjcc.2023.01.008
Source: Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Ryota Nishio Manabu Ogita Satoru Suwa Koichi Nakao Yukio Ozaki Kazuo Kimura Junya Ako Teruo Noguchi Kazuteru Fujimoto Kazuoki Dai Takashi Morita Wataru Shimizu Yoshihiko Saito Atsushi Hirohata Yasuhiro Morita Teruo Inoue Atsunori Okamura Toshiaki Mano Min Source Type: research

Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta - analysis
CONCLUSION: Shortened DAPT signifcantly reduced the odds of major bleedings in patients undergoing complex PCI, without increasing the ischemic events or mortality. Thus, it could be considered as a safe and feasible option in such patients.PMID:36736730 | DOI:10.1016/j.hjc.2023.01.005
Source: Hellenic Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Anastasios Apostolos Dimitrios Chlorogiannis Georgios Vasilagkos Konstantinos Katsanos Konstantinos Toutouzas Adel Aminian Dimitrios Alexopoulos Periklis Davlouros Grigorios Tsigkas Source Type: research

Shorter door-to-balloon time, better long-term clinical outcomes in ST-segment elevation myocardial infarction patients: J-MINUET Substudy
CONCLUSION: Shorter DTB time was associated with better long-term clinical outcomes in STEMI patients treated with PPCI in contemporary clinical practice. Further efforts to shorten DTB time are recommended to improve long-term clinical outcomes in STEMI patients.PMID:36736534 | DOI:10.1016/j.jjcc.2023.01.008
Source: Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Ryota Nishio Manabu Ogita Satoru Suwa Koichi Nakao Yukio Ozaki Kazuo Kimura Junya Ako Teruo Noguchi Kazuteru Fujimoto Kazuoki Dai Takashi Morita Wataru Shimizu Yoshihiko Saito Atsushi Hirohata Yasuhiro Morita Teruo Inoue Atsunori Okamura Toshiaki Mano Min Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research